Gilead Sciences Inc

$ 63.04 1.17 (1.89%)
On watch
Volume: 10,168,916 Avg Vol (1m): 7,069,538
Market Cap $: 80.37 Bil Enterprise Value $: 77.75 Bil
P/E (TTM): 15.17 P/B: 3.75
Earnings Power Value 85.22
Net Current Asset Value -5.03
Tangible Book 1.2
Projected FCF 146.31
Median P/S Value 78.59
Graham Number 10.58
Peter Lynch Value 56.1
DCF (FCF Based) 162.9
DCF (Earnings Based) 118.43
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 1.10
Equity-to-Asset 0.34
Debt-to-Equity 1.28
Debt-to-EBITDA 2.65
Interest Coverage 7.61
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.82
DISTRESS
GREY
SAFE
Beneish M-Score -2.94
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 23.97%
WACC 7.69%

Profitability & Growth : 9/10

Current vs industry vs history
Operating Margin % 37.06
Net Margin % 24.65
ROE % 25.50
ROA % 8.29
ROC (Joel Greenblatt) % 244.30
3-Year Total Revenue Growth Rate -12.20
3-Year Total EBITDA Growth Rate -24.00
3-Year EPS w/o NRI Growth Rate -29.50
N/A

» GILD's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GILD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare OCSE:NOVO B NAS:AMGN NAS:CELG ASX:CSL NAS:BIIB LSE:SHP NAS:VRTX NAS:REGN XKRX:068270 XKRX:207940 NAS:ALXN HKSE:01177 XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV
Traded in other countries GILD34.Brazil GIS.Germany
Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Ratios

Current vs industry vs history
PE Ratio (TTM) 15.17
Forward PE Ratio 9.38
N/A
PE Ratio without NRI 15.17
Price-to-Owner-Earnings 14.59
PB Ratio 3.75
PS Ratio 3.69
Price-to-Free-Cash-Flow 11.00
Price-to-Operating-Cash-Flow 9.80
EV-to-EBIT 8.76
EV-to-EBITDA 7.56
EV-to-Revenue 3.49
PEG Ratio 0.87
Shiller PE Ratio 13.18
Current Ratio 3.38
Quick Ratio 3.30
Days Inventory 62.80
Days Sales Outstanding 54.88
Days Payable 59.42

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.73
Dividend Payout Ratio 0.55
3-Year Dividend Growth Rate (Per Share) 20.90
Forward Dividend Yield % 4.07
N/A
Yield-on-Cost (5-Year) % 3.73
3-Year Share Buyback Rate 3.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 52.53
Price-to-Projected-FCF 0.43
Price-to-DCF (Earnings Based) 0.53
Price-to-Median-PS-Value 0.80
Price-to-Peter-Lynch-Fair-Value 1.12
Price-to-Graham-Number 5.96
Earnings Yield (Joel Greenblatt) % 11.41
Forward Rate of Return (Yacktman) % 27.87

More Statistics

Revenue (TTM) (Mil) $ 22,127
EPS (TTM) $ 4.16
Beta 1.23
Volatility % 27.95
52-Week Range $ 60.32 - 79.61
Shares Outstanding (Mil) 1,274.9

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N